JP7125348B2 - ＰＧＣ－１αの発現を増加させる組成物 - Google Patents

ＰＧＣ－１αの発現を増加させる組成物 Download PDF

Info

Publication number
JP7125348B2
JP7125348B2 JP2018536439A JP2018536439A JP7125348B2 JP 7125348 B2 JP7125348 B2 JP 7125348B2 JP 2018536439 A JP2018536439 A JP 2018536439A JP 2018536439 A JP2018536439 A JP 2018536439A JP 7125348 B2 JP7125348 B2 JP 7125348B2
Authority
JP
Japan
Prior art keywords
pgc
group
composition
disease
gene expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018536439A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019502718A5 (enExample
JP2019502718A (ja
Inventor
スンウ・カン
Original Assignee
ベネバイオシス カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベネバイオシス カンパニー リミテッド filed Critical ベネバイオシス カンパニー リミテッド
Publication of JP2019502718A publication Critical patent/JP2019502718A/ja
Publication of JP2019502718A5 publication Critical patent/JP2019502718A5/ja
Priority to JP2022128627A priority Critical patent/JP7467543B2/ja
Application granted granted Critical
Publication of JP7125348B2 publication Critical patent/JP7125348B2/ja
Priority to JP2024059854A priority patent/JP2024081767A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04—Disaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/332—Promoters of weight control and weight loss

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
JP2018536439A 2016-01-13 2017-01-13 ＰＧＣ－１αの発現を増加させる組成物 Active JP7125348B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022128627A JP7467543B2 (ja) 2016-01-13 2022-08-12 ＰＧＣ－１αの発現を増加させる組成物
JP2024059854A JP2024081767A (ja) 2016-01-13 2024-04-03 ＰＧＣ－１αの発現を増加させる組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160004383 2016-01-13
KR10-2016-0004383 2016-01-13
PCT/KR2017/000505 WO2017123066A1 (ko) 2016-01-13 2017-01-13 Pgc-1알파의 발현을 증가시키는 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022128627A Division JP7467543B2 (ja) 2016-01-13 2022-08-12 ＰＧＣ－１αの発現を増加させる組成物

Publications (3)

Publication Number Publication Date
JP2019502718A JP2019502718A (ja) 2019-01-31
JP2019502718A5 JP2019502718A5 (enExample) 2020-02-20
JP7125348B2 true JP7125348B2 (ja) 2022-08-24

Family

ID=59311711

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018536439A Active JP7125348B2 (ja) 2016-01-13 2017-01-13 ＰＧＣ－１αの発現を増加させる組成物
JP2022128627A Active JP7467543B2 (ja) 2016-01-13 2022-08-12 ＰＧＣ－１αの発現を増加させる組成物
JP2024059854A Pending JP2024081767A (ja) 2016-01-13 2024-04-03 ＰＧＣ－１αの発現を増加させる組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022128627A Active JP7467543B2 (ja) 2016-01-13 2022-08-12 ＰＧＣ－１αの発現を増加させる組成物
JP2024059854A Pending JP2024081767A (ja) 2016-01-13 2024-04-03 ＰＧＣ－１αの発現を増加させる組成物

Country Status (12)

Country Link
US (1) US20190030053A1 (enExample)
EP (2) EP3403655B1 (enExample)
JP (3) JP7125348B2 (enExample)
KR (3) KR20180099885A (enExample)
CN (3) CN120643579A (enExample)
CA (2) CA3010338C (enExample)
ES (1) ES2946945T3 (enExample)
HK (1) HK1257689A1 (enExample)
MX (2) MX389553B (enExample)
MY (1) MY197561A (enExample)
SG (1) SG11201805791RA (enExample)
WO (1) WO2017123066A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3498282A1 (en) * 2017-12-12 2019-06-19 Rheinische Friedrich-Wilhelms-Universität Bonn 6'-sialyllactose for use in the treatment of hearing loss
US11234992B2 (en) * 2018-02-28 2022-02-01 The Regents Of The University Of California Methods and therapies for treating atherosclerosis and/or hyperlipidemia using oligosaccharides
AU2020230410A1 (en) * 2019-03-05 2021-09-02 Société des Produits Nestlé S.A. A nutritional composition for use to enhance executive function
MX2021010289A (es) * 2019-03-05 2022-02-10 Glycom As Oligosacaridos de leche humana para uso en el mejoramiento de la funcion ejecutiva.
JP2021038147A (ja) * 2019-08-30 2021-03-11 国立大学法人 鹿児島大学 ミトコンドリア生合成促進剤
KR102186761B1 (ko) * 2020-06-03 2020-12-04 옙바이오 주식회사 2-(4-(1-하이드록시프로판-2-일)페닐)이소인돌린-1-온 화합물을 포함하는 파킨슨병 예방 또는 치료용 약학적 조성물
GB202114190D0 (en) * 2021-10-04 2021-11-17 Mjn Us Holdings Llc Compositions for preventing and/or treating demyelination
CN121100111A (zh) * 2023-06-02 2025-12-09 兹杜斯生命科学有限公司 用于肌萎缩侧索硬化(als)的治疗

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529877A (ja) 2008-08-01 2011-12-15 ベネバイオシス カンパニー リミテッド 高脂血症、脂肪肝又は肥満の予防又は治療用組成物
US20120122814A1 (en) 2009-04-09 2012-05-17 Benebiosis Co., Ltd. Composition for Prevention or Treatment of Hypertrophic Scars or Keloids
WO2014100126A1 (en) 2012-12-18 2014-06-26 Abbott Laboratories Human milk oligosaccharides to ameliorate symptoms of stress
WO2014100191A1 (en) 2012-12-18 2014-06-26 Abbott Laboratories Nutritional compositions comprising neuroprotective dietary oligosaccharides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164374A (en) * 1990-12-17 1992-11-17 Monsanto Company Use of oligosaccharides for treatment of arthritis
JPH07258093A (ja) * 1994-03-23 1995-10-09 Morinaga Milk Ind Co Ltd 神経成長因子様剤
KR20110092602A (ko) * 2010-02-09 2011-08-18 주식회사 베네비오 플라스미노겐 활성 억제인자-1의 억제제
SG10202110501RA (en) * 2010-12-31 2021-11-29 Abbott Lab Methods For Decreasing The Incidence Of Necrotizing Enterocolitis In Infants, Toddlers, Or Children Using Human Milk Oligosaccharides
DE112013004483T5 (de) * 2012-09-14 2015-06-03 Robert Bosch Gmbh Überprüfung einer Vorrichtung unter Verwenden eines Versperrens einer akustischen Öffnung
DE102013208103A1 (de) 2013-05-03 2014-11-06 Siemens Aktiengesellschaft Röntgenquelle und bildgebendes System
WO2016145628A1 (en) * 2015-03-18 2016-09-22 Nestec S.A. Composition comprising siallyllactose for use in enhancing learning skills and memory function

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529877A (ja) 2008-08-01 2011-12-15 ベネバイオシス カンパニー リミテッド 高脂血症、脂肪肝又は肥満の予防又は治療用組成物
US20120122814A1 (en) 2009-04-09 2012-05-17 Benebiosis Co., Ltd. Composition for Prevention or Treatment of Hypertrophic Scars or Keloids
WO2014100126A1 (en) 2012-12-18 2014-06-26 Abbott Laboratories Human milk oligosaccharides to ameliorate symptoms of stress
WO2014100191A1 (en) 2012-12-18 2014-06-26 Abbott Laboratories Nutritional compositions comprising neuroprotective dietary oligosaccharides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Brain Behavior and Immunity，2015年，Vol.50，pp.166-177
Brain，2014年，Vol.137，pp.2670-2679
J.Appl.Glycosci.，Vol.53，2006年，pp.249-254

Also Published As

Publication number Publication date
KR20210079376A (ko) 2021-06-29
EP3403655A4 (en) 2019-08-07
CN120661527A (zh) 2025-09-19
US20190030053A1 (en) 2019-01-31
CN108472305A (zh) 2018-08-31
WO2017123066A1 (ko) 2017-07-20
JP2022166164A (ja) 2022-11-01
MX2022000945A (es) 2022-02-14
SG11201805791RA (en) 2018-08-30
ES2946945T3 (es) 2023-07-28
MX389553B (es) 2025-03-20
KR20180099885A (ko) 2018-09-05
EP3845233A1 (en) 2021-07-07
MX2018008671A (es) 2019-02-13
KR20230107718A (ko) 2023-07-17
JP2019502718A (ja) 2019-01-31
CA3010338C (en) 2023-08-22
JP2024081767A (ja) 2024-06-18
CA3010338A1 (en) 2017-07-20
RU2018128408A (ru) 2020-02-13
CN120643579A (zh) 2025-09-16
EP3403655C0 (en) 2023-06-07
EP3403655B1 (en) 2023-06-07
HK1257689A1 (zh) 2019-10-25
KR102771814B1 (ko) 2025-02-26
JP7467543B2 (ja) 2024-04-15
RU2018128408A3 (enExample) 2020-02-13
CA3203927A1 (en) 2017-07-20
MY197561A (en) 2023-06-23
EP3403655A1 (en) 2018-11-21

Similar Documents

Publication Publication Date Title
JP7467543B2 (ja) ＰＧＣ－１αの発現を増加させる組成物
JP7214268B2 (ja) 皮膚用組成物
JP6258988B2 (ja) 高麗人参の実抽出物を含有する血行促進、血管老化防止及び虚血性心疾患治療用組成物
CN101111244B (zh) 含有山奈酚和槲皮素的透明质酸生成促进用组合物
CA3055164A1 (en) Composition for inhibiting myofibrosis
CN104780927A (zh) 转谷氨酰胺酶活化剂
KR102496282B1 (ko) 사이토칼라신 d 또는 sag를 포함하는 항노화용 조성물 및 항노화 물질 스크리닝 방법
WO2010150612A1 (ja) ヒアルロン酸産生促進剤及びメラニン生成抑制剤
RU2814560C2 (ru) КОМПОЗИЦИЯ ДЛЯ ПОВЫШЕНИЯ ЭКСПРЕССИИ PGC-1α
JP5392742B2 (ja) メラニン生成阻害剤
JP2008260700A (ja) 脂肪蓄積および脂肪細胞分化を抑制するための組成物
EP3777865A1 (en) Anti-aging composition

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200108

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211012

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220411

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220527

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220712

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220812

R150 Certificate of patent or registration of utility model

Ref document number: 7125348

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250